Melanotransferrin: A “Missing Link” and a Novel Pharmacological Target for Treatment

黑素转铁蛋白：一个“缺失的环节”和一个新的治疗药理学靶点

• 批准号: nhmrc : 1144829
• 负责人: Dr Darius Lane
• 金额: $ 41.5万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/melanotransferrin-missing-link-target-treatment/1320292
• 关键词: Melanotransferrin; Missing; Link; Novel; Pharmacological

Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.

尽管经过30年的研究，黑素转铁蛋白（MTF）的确切功能仍然未知。然而，我们有突破性的证据表明，MTF刺激WNT信号传导是癌症进展的主要驱动因素。我们将研究这一假设，这将为新的癌症疗法奠定基础。事实上，我们设计了一类新的药物，通过上调WNT抑制剂NDRG1靶向WNT通路。这种药物（DpC）抑制MTF表达以阻断肿瘤细胞生长和转移。